{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:26:54Z","timestamp":1793424414020,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["755021"],"award-info":[{"award-number":["755021"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:21:55Z","timestamp":1789125715000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9951-3591","authenticated-orcid":false,"given":"Marlies","family":"Destoop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela S.","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris A.L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelotte M.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlou C.","family":"Bierlaagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia F.","family":"Boj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.J.","family":"Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"De Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis K.","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Spelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcf.2026.09.004_bib0001","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2026.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.jcf.2026.09.004_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jcf.2026.09.004_bib0005","unstructured":"CFTR mutation database. [Available from: https:\/\/www.genet.sickkids.on.ca\/."},{"issue":"17","key":"10.1016\/j.jcf.2026.09.004_bib0006","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.09.004_bib0007","unstructured":"Woolford J. Eloxx pharmaceuticals reports positive topline results from monotherapy arms of phase 2 clinical trial of ELX-02 in class 1 cystic fibrosis patients 2021 [Available from: https:\/\/investors.eloxxpharma.com\/node\/11986\/pdf."},{"key":"10.1016\/j.jcf.2026.09.004_bib0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.omtn.2021.12.003","article-title":"Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay","volume":"27","author":"Zhao","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"10.1016\/j.jcf.2026.09.004_bib0009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.120.265595","article-title":"ELX-02 generates protein via premature stop codon read-through without inducing native stop codon read-through proteins","volume":"374","author":"Crawford","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jcf.2026.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jcf.2026.09.004_bib0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molmed.2023.01.004","article-title":"Readthrough compounds for nonsense mutations: bridging the translational gap","volume":"29","author":"Spelier","year":"2023","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.09.004_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and effectiveness of ataluren: comparison of results from the STRIDE registry and CINRG DMD natural history study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"10101","key":"10.1016\/j.jcf.2026.09.004_bib0013","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.09.004_bib0014","unstructured":"Woolford J. Eloxx pharmaceuticals reports topline results from phase 2 combination clinical trial of ELX-02 in class 1 cystic fibrosis (CF) patients 2022 [Available from: https:\/\/investors.eloxxpharma.com\/news-releases\/news-release-details\/eloxx-pharmaceuticals-reports-topline-results-phase-2?fbclid=IwAR31GRojriXkl1njErqm3qQCY6-Cw4bgmqP-hzogmDAz58cY9C_2xnjZeXw."},{"issue":"7","key":"10.1016\/j.jcf.2026.09.004_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.09.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"issue":"344","key":"10.1016\/j.jcf.2026.09.004_bib0017","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.09.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2026.09.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02529-2017","article-title":"Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function","volume":"52","author":"de Winter-de Groot","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2026.09.004_bib0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcf.2015.07.007","article-title":"Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids","volume":"15","author":"Zomer-van Ommen","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.09.004_bib0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.09.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00770-2023","article-title":"Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach","volume":"63","author":"Spelier","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2026.09.004_bib0023","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jcf.2024.04.014","article-title":"Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with cystic fibrosis","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2026.09.004_bib0024","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcf.2024.04.016","article-title":"Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe organoid study","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.09.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2026.06.002","article-title":"A functional comparison of vanzacaftor\/tezacaftor\/deutivacaftor and elexacaftor\/tezacaftor\/ivacaftor in patient-derived intestinal organoids with rare CFTR variants","author":"Kroes","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.09.004_bib0026","unstructured":"Vertex. Eligible MF CFTR mutations for a phase 3 study evaluation the pharmcokinetics, safety, and tolerability of VX-445\/TEZ\/IVA triple combination therapy in cystic fibrosis subjects 6 through 11 years of age 2021 Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-12\/Study-VX18-445-106-Eligible-Mutations-June-2019.pdf."},{"issue":"8","key":"10.1016\/j.jcf.2026.09.004_bib0027","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.jcf.2026.09.004_bib0028","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.jcf.2026.09.004_bib0029","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.09.004_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/j.jcf.2026.09.004_bib0031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jcf.2025.08.011","article-title":"Correlation between patient-derived intestinal organoids and clinical responses to CFTR modulators in people with cystic fibrosis homozygous for F508del","volume":"24","author":"Rodriguez Mier","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:50:01Z","timestamp":1789246201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S1569199326037380"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.09.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}